Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275694 | 0.78 | TDP2 (0.35) | TDP2ADAM17HTR2AGRM2 | |
| SCHEMBL10275411 | 0.69 | APP (0.37) | TDP2ALOX5APFEN1ADAM17 | |
| SCHEMBL10275854 | 0.69 | PARK7 (0.31) | — | |
| SCHEMBL10275481 | 0.69 | ADAM17 (0.35) | TDP2ALOX5APFEN1ADAM17HTR2A | |
| SCHEMBL10275773 | 0.66 | APP (0.34) | TDP2ALOX5APFEN1ADAM17 | |
| SCHEMBL10275638 | 0.66 | KCNH2 (0.36) | TDP2ALOX5APFEN1ADAM17 | |
| SCHEMBL10276004 | 0.65 | KCNH2 (0.37) | TDP2ADAM17HTR2AGRM2 | |
| SCHEMBL11545227 | 0.63 | TAAR1 (0.50) | TDP2ALOX5APFEN1GRM2CYP3A4 | |
| SCHEMBL10275697 | 0.61 | PDE3B (0.34) | TDP2ALOX5APFEN1HTR2AGRM2 | |
| SCHEMBL10276613 | 0.61 | PDE3B (0.32) | TDP2ALOX5APFEN1HTR2AGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | TDP2 1492/4885ALOX5AP 1631/4885FEN1 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.